Wave Life Financials
| WVE Stock | USD 14.99 0.16 1.08% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | 1.2625 |
|
|
Investors should never underestimate Wave Life's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Wave Life's cash flow, debt, and profitability to make informed and accurate decisions about investing in Wave Life Sciences.
Net Income |
|
Wave | Select Account or Indicator |
Understanding current and past Wave Life Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Wave Life's financial statements are interrelated, with each one affecting the others. For example, an increase in Wave Life's assets may result in an increase in income on the income statement.
Please note, the presentation of Wave Life's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Wave Life's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Wave Life's management manipulating its earnings.
Wave Life Stock Summary
Wave Life competes with Arrowhead Pharmaceuticals, CytomX Therapeutics, Assembly Biosciences, Apellis Pharmaceuticals, and Iteos Therapeutics. Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company was incorporated in 2012 and is based in Singapore. Wave Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | SG9999014716 |
| CUSIP | Y95308105 |
| Location | Singapore |
| Business Address | Marina One East |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.wavelifesciences.com |
| Phone | 65 6236 3388 |
| Currency | USD - US Dollar |
Wave Life Key Financial Ratios
| Return On Equity | -2.44 | ||||
| Profit Margin | (2.66) % | ||||
| Operating Margin | 8.33 % | ||||
| Price To Sales | 42.65 X | ||||
| Revenue | 113.31 M |
Wave Life Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 284.3M | 279.2M | 207.0M | 146.4M | 274.9M | 200.5M | |
| Other Current Liab | 16.2M | 8.3M | 9.9M | 12.1M | 10.1M | 8.5M | |
| Other Liab | 65.2M | 42.0M | 77.5M | 80.0M | 92.0M | 96.6M | |
| Net Debt | (114.6M) | (155.2M) | (120.6M) | (50.9M) | (168.2M) | (176.6M) | |
| Retained Earnings | (533.4M) | (683.3M) | (805.5M) | (967.3M) | (1.0B) | (973.6M) | |
| Accounts Payable | 9.1M | 13.8M | 7.3M | 16.9M | 12.8M | 8.9M | |
| Cash | 147.2M | 184.5M | 150.6M | 88.5M | 200.4M | 140.1M | |
| Other Assets | 44.3M | 3.8M | 3.8M | 3.7M | 4.3M | 4.1M | |
| Net Receivables | 10M | 20M | 30M | 0.0 | 21.1M | 22.1M | |
| Other Current Assets | 8.7M | 15.5M | 12M | 10.0M | 13.9M | 8.7M | |
| Total Liab | 220.5M | 196.5M | 174.5M | 191.5M | 227.4M | 132.8M | |
| Total Current Assets | 185.5M | 230.0M | 162.6M | 98.5M | 235.4M | 158.0M | |
| Short Term Debt | 3.2M | 7.4M | 9.9M | 11.0M | 13.4M | 14.1M | |
| Common Stock | 539.5M | 694.1M | 749.9M | 802.8M | 935.4M | 481.8M | |
| Net Tangible Assets | 63.7M | 90.7M | 40.4M | (37.2M) | (33.5M) | (31.8M) | |
| Capital Surpluse | 57.3M | 71.6M | 88.0M | 119.4M | 137.4M | 144.2M | |
| Net Invested Capital | 63.7M | 82.8M | 32.5M | (45.1M) | 39.6M | 44.2M | |
| Net Working Capital | 67.3M | 109.0M | 98.4M | 27.0M | 48.9M | 63.3M |
Wave Life Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Operating Income | (208.3M) | (153.4M) | (127.0M) | (162.7M) | (68.0M) | (71.4M) | |
| Ebit | (208.3M) | (153.4M) | (127.0M) | (162.7M) | (68.0M) | (71.4M) | |
| Research Development | 175.4M | 130.9M | 121.9M | 115.9M | 130.0M | 94.2M | |
| Ebitda | (213.2M) | (143.4M) | (117.2M) | (152.6M) | (58.8M) | (61.7M) | |
| Income Before Tax | (193.6M) | (150.8M) | (122.4M) | (161.1M) | (58.2M) | (61.1M) | |
| Net Income | (179.5M) | (149.9M) | (122.2M) | (161.8M) | (57.5M) | (60.4M) | |
| Income Tax Expense | (14.1M) | (841K) | (204K) | 681K | (677K) | (710.9K) | |
| Total Revenue | 16.0M | 20.1M | 41.0M | 3.6M | 113.3M | 119.0M | |
| Gross Profit | (159.4M) | (104.1M) | (80.9M) | 3.6M | 104.1M | 109.3M | |
| Cost Of Revenue | 175.4M | 124.2M | 121.9M | 10.1M | 9.2M | 8.7M | |
| Tax Provision | 0.0 | (841K) | (204K) | 681K | (677K) | (643.2K) | |
| Interest Income | 1.6M | 3.4M | 4.9M | 1.6M | 1.8M | 2.2M | |
| Net Interest Income | 22K | 29K | (16K) | 1.6M | 1.8M | 1.9M |
Wave Life Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (27.6M) | 37.3M | (33.9M) | (62.1M) | 111.9M | 117.5M | |
| Free Cash Flow | (192.1M) | (117.3M) | (89.6M) | (129.1M) | (20.5M) | (21.6M) | |
| Depreciation | 9.2M | 10.0M | 9.8M | 10.1M | 9.2M | 5.8M | |
| Other Non Cash Items | 31.4M | 9.1M | 12.6M | 12K | (24.8M) | (23.6M) | |
| Capital Expenditures | 3.9M | 1.3M | 560K | 1.4M | 1.1M | 1.1M | |
| Net Income | (193.6M) | (149.9M) | (122.2M) | (161.8M) | (57.5M) | (60.4M) | |
| End Period Cash Flow | 150.8M | 188.1M | 154.2M | 92.2M | 204.1M | 142.3M | |
| Change To Inventory | (4.1M) | (5.5M) | 4.6M | 2.0M | 2.3M | 2.5M | |
| Change To Netincome | 19.5M | 14.3M | 16.4M | 17.2M | 19.8M | 13.5M | |
| Investments | (3.9M) | (1.3M) | (560K) | (1.3M) | (1.1M) | (1.2M) |
Wave Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Wave Life's current stock value. Our valuation model uses many indicators to compare Wave Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Wave Life competition to find correlations between indicators driving Wave Life's intrinsic value. More Info.Wave Life Sciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Wave Life's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Wave Life by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Wave Life Sciences Systematic Risk
Wave Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Wave Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Wave Life Sciences correlated with the market. If Beta is less than 0 Wave Life generally moves in the opposite direction as compared to the market. If Wave Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Wave Life Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Wave Life is generally in the same direction as the market. If Beta > 1 Wave Life moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Wave Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Wave Life's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Wave Life growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Wave Life November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Wave Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Wave Life Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Wave Life Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Wave Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Wave Life's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.94 | |||
| Information Ratio | 0.1574 | |||
| Maximum Drawdown | 82.93 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 10.86 |
Complementary Tools for Wave Stock analysis
When running Wave Life's price analysis, check to measure Wave Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Wave Life is operating at the current time. Most of Wave Life's value examination focuses on studying past and present price action to predict the probability of Wave Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Wave Life's price. Additionally, you may evaluate how the addition of Wave Life to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |